Lupin receives USFDA approval for Mycophenolic Acid Delayed-Release Tablets

Lupin in alliance with Concord Biotech announced that it has received approval from the United States Food and Drug Administration (USFDA) for Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, to market the generic equivalent of Myfortic Delayed-Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation.

Powered by Capital Market - Live News